Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension

A Pilot Phase IIa Randomised, Double-blind, Placebo-controlled, Crossover Study to Examine the Safety, Tolerability and Pharmacodynamic Effects on Blood Pressure of Repeat Oral Doses of SLx-2101 5, 10 or 20 mg Once Daily for up to 14 Days in Patients With Hypertension

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00562549

Enrollment

Registered

2007-11-22

Start date

2007-07-01

Completion date

2007-12-01

Last updated

2026-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

The purpose is to determine the effective dosage and to study the effects of this dosage taken for 12 days on systolic and diastolic blood pressure in patients with hypertension.

Detailed description

1. Office seated peripheral systolic and diastolic blood pressure 2. Adverse events and vital signs 3. Plasma concentrations of SLx-2101

Interventions

DRUGSLx-2101

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Male or females between 18 and 80 years, inclusive * Moderate to severe hypertension * Body weight within a body mass index range of 18 - 32 kg/m2

Exclusion criteria

* Subject is receiving more than four antihypertensive agents * History of drug abuse * Exposure to a new chemical entity within 3 months prior to the first day of dosing

Design outcomes

Primary

Measure	Time frame
Office seated peripheral systolic and diastolic blood pressure	12 days

Secondary

Measure	Time frame
Adverse events and changes in vital signs	12 days

Countries

United Kingdom

Contacts

PRINCIPAL_INVESTIGATORIan B Wilkinson, MD

Addenbrooke's Hospital, Cambridge

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 1, 2026